OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor α. We undertook to determine the long-term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open-label extension study (ClinicalTrials.gov identifier: NCT01712399). METHODS: In study 1071, patients with an inadequate response to disease-modifying antirheumatic drugs (DMARDs) received mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate. In study 1107, patients with an inadequate response to anti-tumor necrosis factor agents and/or DMARDs received 100 mg mavrilimumab every other week or 50 mg golimumab every 4 weeks plus methotrexate. Patients entering the open-label extension study received 100 mg mavrilimumab every other week plus methotrexate. Long-term safety and efficacy of mavrilimumab were assessed. RESULTS: A total of 442 patients received mavrilimumab (14 of 245 patients from study 1071, 9 of 70 patients from study 1107, and 52 of 397 patients from the open-label extension study discontinued mavrilimumab treatment throughout the studies). The cumulative safety exposure was 899 patient-years; the median duration of mavrilimumab treatment was 2.5 years (range 0.1-3.3 years). The most common treatment-emergent adverse events (AEs) were nasopharyngitis (n = 69; 7.68 per 100 patient-years) and bronchitis (n = 51; 5.68 per 100 patient-years). At weeks 74 and 104, 3.5% and 6.2% of patients, respectively, demonstrated reduction in forced expiratory volume in 1 second, while 2.9% and 3.4% of patients, respectively, demonstrated reduction in forced vital capacity (>20% reduction from baseline to <80% predicted). Most pulmonary changes were transient and only infrequently associated with AEs. Mavrilimumab at 100 mg every other week demonstrated sustained efficacy; at week 122, 65.0% of patients achieved a Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) of <3.2, and 40.6% of patients achieved a DAS28-CRP of <2.6. CONCLUSION: Long-term treatment with mavrilimumab maintained response and was well-tolerated with no increased incidence of treatment-emergent AEs. Safety data were comparable with those from both phase IIb qualifying studies.

Brigham and Women's Hospital Boston Massachusetts

Centro de Estudios Reumatológicos Santiago Chile

Charité University Medicine Berlin Berlin Germany

Institute of Rheumatology Prague Czech Republic

MedImmune Cambridge UK

MedImmune Gaithersburg Maryland

The Albany Medical College Albany New York

University of Glasgow Glasgow UK

Zobrazit více v PubMed

Van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord 2016;17:184. PubMed PMC

Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53–61. PubMed

Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta‐analysis. Lancet 2015;386:258–65. PubMed PMC

Berghen N, Teuwen LA, Westhovens R, Verschueren P. Malignancies and anti‐TNF therapy in rheumatoid arthritis: a single‐center observational cohort study. Clin Rheumatol 2015;34:1687–95. PubMed

Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G‐CSF and GM‐CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009;5:554–9. PubMed

Avci AB, Feist E, Burmester GR. Targeting GM‐CSF in rheumatoid arthritis. Clin Exp Rheumatol 2016;34 Suppl 98:39–44. PubMed

Greven DE, Cohen ES, Gerlag DM, Campbell J, Woods J, Davis N, et al. Preclinical characterisation of the GM‐CSF receptor as a therapeutic target in rheumatoid arthritis. Ann Rheum Dis 2015;74:1924–30. PubMed PMC

Cook AD, Louis C, Robinson MJ, Saleh R, Sleeman MA, Hamilton JA. Granulocyte macrophage colony‐stimulating factor receptor α expression and its targeting in antigen‐induced arthritis and inflammation. Arthritis Res Ther 2016;18:287. PubMed PMC

Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocyte‐macrophage colony‐stimulating factor. Crit Rev Immunol 2005;25:405–28. PubMed

Hamilton JA. Colony‐stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008;8:533–44. PubMed

Zhan Y, Cheers C. Haemopoiesis in mice genetically lacking granulocyte‐macrophage colony stimulating factor during chronic infection with Mycobacterium avium. Immunol Cell Biol 2000;78:118–23. PubMed

Calisto Perez C, Leon R, Leon F, Ng SL. Rheumatoid arthritis and anemia: the impact of different anti‐inflammatory therapies on hemoglobin levels: an observational study. Bol Asoc Med P R 2012;104:34–41. PubMed

Lazaro E, Morel J. Management of neutropenia in patients with rheumatoid arthritis. Joint Bone Spine 2015;82:235–9. PubMed

Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther 2017;11:211–23. PubMed PMC

Chen BD, Mueller M, Chou TH. Role of granulocyte/macrophage colony‐stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 1988;141:139–44. PubMed

Akagawa KS, Kamoshita K, Tokunaga T. Effects of granulocyte‐macrophage colony‐stimulating factor and colony‐stimulating factor‐1 on the proliferation and differentiation of murine alveolar macrophages. J Immunol 1988;141:3383–90. PubMed

Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM‐CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001;15:557–67. PubMed

Yoshida M, Korfhagen TR, Whitsett JA. Surfactant protein D regulates NF‐κ B and matrix metalloproteinase production in alveolar macrophages via oxidant‐sensitive pathways. J Immunol 2001;166:7514–9. PubMed

Borie R, Danel C, Debray MP, Taille C, Dombret MC, Aubier M, et al. Pulmonary alveolar proteinosis. Eur Respir Rev 2011;20:98–107. PubMed PMC

Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, et al. Protein engineering and preclinical development of a GM‐CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol 2013;168:200–11. PubMed PMC

Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013;72:1445–52. PubMed PMC

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, et al. A randomised phase IIb study of mavrilimumab, a novel GM‐CSF receptor α monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017;76:1020–30. PubMed

Weinblatt M, McInnes I, Kremer J, Miranda P, Vencovsky J, Godwin D, et al. EARTH EXPLORER 2, a phase IIb exploratory study evaluating efficacy and safety of mavrilimumab, a fully human granulocyte‐macrophage colony‐stimulating factor receptor‐α monoclonal antibody, and the tumor necrosis factor antagonist golimumab in rheumatoid arthritis. Ann Rheum Dis 2016;75:717–8.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81. PubMed

Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty‐eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8. PubMed

Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845–50. PubMed

Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81. PubMed

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35. PubMed

Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806. PubMed PMC

Van der Heijde DM, van Riel PL, Gribnau FW, Nuver‐Zwart IH, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036–8. PubMed

Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45. PubMed

Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF‐36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.

Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811–9. PubMed

Achuthan A, Cook AD, Lee MC, Saleh R, Khiew HW, Chang MW, et al. Granulocyte macrophage colony‐stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J Clin Invest 2016;126:3453–66. PubMed PMC

Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M‐CSF‐generated macrophages and comparison of M1‐markers in classically activated macrophages from GM‐CSF and M‐CSF origin. Cell Immunol 2013;281:51–61. PubMed

Guo X, Wang S, Bay‐Jensen AC, Karsdal MA, Godwood A, Albulescu M, et al. Sustained suppression of peripheral biomarkers by mavrilimumab but not golimumab in anti‐tumor necrosis factor‐inadequate responders: an exploratory analysis in the phase IIb Earth Explorer 2 Clinical Trial [abstract]. Arthritis Rheumatol 2016;68 Suppl 10 URL: http://acrabstracts.org/abstract/sustained-suppression-of-peripheral-biomarkers-by-mavrilimumab-but-not-golimumab-in-anti-tumor-necrosis-factor-inadequate-responders-an-exploratory-analysis-in-the-phase-iib-earth-explorer-2-clinical/.

Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007;4:443–8. PubMed PMC

Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011;37:1411–7. PubMed

Kelly C, Iqbal K, Iman‐Gutierrez L, Evans P, Manchegowda K. Lung involvement in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2016;30:870–88. PubMed

Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis‐associated lung disease. Eur Respir Rev 2015;24:1–16. PubMed PMC

Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long‐term low‐dose methotrexate. Chest 1996;109:933–8. PubMed

Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low‐dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002;41:262–7. PubMed

Antoniu SA. GM‐CSF pathway correction in pulmonary alveolar proteinosis. Expert Opin Biol Ther 2010;10:1357–65. PubMed

Khan A, Agarwal R. Pulmonary alveolar proteinosis. Respir Care 2011;56:1016–28. PubMed

Buch MH, Silva‐Fernandez L, Carmona L, Aletaha D, Christensen R, Combe B, et al. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis 2015;74:963–9. PubMed PMC

Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01712399